AgomAb Therapeutics N.V. American Depositary Shares

NASDAQ:AGMB

Biotechnology

Healthcare
$5.82 +2.48%

+$0.25 today

Market cap
$286.62M
Beta
2.62
P/E (TTM)
-7.1
EPS (TTM)
-$1.28
52W Low $8.75High $17.45

Volume 0.13M

Average 0.14M

AGMB Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB

Weighted Avg Shares (Diluted) · Q4 FY2024 · quarter ended Dec 2024

Weighted avg shares (diluted) of 36.24M shares in Q4 FY2024

Q4 FY2024 weighted avg shares (diluted) was 36.24M shares.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 2 fiscal years.
  • FY2024 was the highest annual figure in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2024
36.24M— QoQ
Last fiscal yearDec 2024
36.24M+0.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2024
36.24M EUR
Year-over-year change
+0.0%
2-year CAGR
+0.0%

Weighted Avg Shares (Diluted) vs competitors

How AGMB compares with its peers on the latest reported figures

  • AGMB's FY2024 weighted avg shares (diluted) of 36.24M shares is the 4th highest of the 5 companies compared; the peer median is 90.14M shares.
  • Its year-over-year change of +0.0% is the lowest of 5, against a peer median of +59.7%.
AGMB Competitors Peer median
Weighted Avg Shares (Diluted) for AGMB and competitors
Company Period LTM YoY 3-year CAGR
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.6%+384.0%
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY202436.24M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding AGMB) 90.14M+59.7%+31.6%

Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development19.42M26.31M39.31M
Selling, General & Admin4.49M6M9.82M
Operating Expenses22.63M31.19M48.02M
Depreciation & Amortization23K99K311K
EBITDA(10.74M)(11.88M)(45.89M)
EBITDA Margin———
Operating Income(22.63M)(31.19M)(48.02M)
Operating Margin———
Interest Income71K245K1.22M
Interest Expense45K31K67K
Other Income / Expenses11.83M19.18M1.76M
Income Before Tax(10.81M)(12.01M)(46.26M)
Pre-Tax Margin———
Income Tax Expense(2.66M)(619K)4K
Net Income(8.14M)(11.39M)(46.27M)
Net Margin———
EPS (Basic)(0.22)(0.31)(1.26)
EPS (Diluted)(0.22)(0.31)(1.26)
Weighted Avg Shares36.24M36.24M36.24M
Weighted Avg Shares (Diluted)36.24M36.24M36.24M

AgomAb Therapeutics N.V. American Depositary Shares

NASDAQ:AGMB

Intrinsic Alpha fair value

Locked

Current Price

$5.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.